Alpha-Defensin vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Alpha-Defensin
Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | Alpha-Defensin | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Dose Range | 100 mcg–500 mcg | 100 mcg–200 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 2–4 weeks | 2–8 weeks |
| Route | subcutaneous | intranasal |
| Mechanism | Insert into microbial membranes to form pores, leading to cell death. Also have immunomodulatory effects including chemotaxis of immune cells and cytokine modulation. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Research compound - dosing varies by application. Typically studied in laboratory and early clinical research settings rather than for general use. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Various routes studied including topical, local injection, and systemic administration depending on application. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Limited human use data. May cause local inflammation. Potential for immune activation effects. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |
What They Have in Common
Alpha-Defensin, VIP (Vasoactive Intestinal Peptide) are both commonly used for:
Key Differences
Unique to Alpha-Defensin:
Unique to VIP (Vasoactive Intestinal Peptide):
Which Has Stronger Evidence?
- Immune Support: Alpha-Defensin has stronger research support.
| Goal | Alpha-Defensin | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Immune Support | high | medium |
Key Studies
Alpha-Defensin
- AhR Activation Transcriptionally Induces Anti-Microbial Peptide Alpha-Defensin 1 Leading to Reversal of Gut Microbiota Dysbiosis and Colitis.
Gut microbes, 2025
- Alpha-defensin binding expands human adenovirus tropism.
PLoS pathogens, 2024
- Alpha-Defensin 1: An Emerging Periodontitis Biomarker.
Diagnostics (Basel, Switzerland), 2023
VIP (Vasoactive Intestinal Peptide)
- Distribution of vasoactive intestinal peptide (VIP) immunoreactivity in the rat pallial and subpallial amygdala and colocalization with γ-aminobutyric acid (GABA).
Anatomical record (Hoboken, N.J. : 2007), 2024
- Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF.
Frontiers in endocrinology, 2024
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis.
Frontiers in pharmacology, 2021
Ready to Learn More?
Looking for trusted sources?